ALNY · NASDAQ · STOCK
Alnylam Pharmaceuticals (ALNY) Stock Analysis
$232.67
52W $197.81 – $495.55
52/100
$31.13B
38.1
0.27
Is ALNY Bullish or Bearish?
Mixed.
Innellis AI committee rates Alnylam Pharmaceuticals (ALNY) Watch with a composite score of 52/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +7.82 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -12.18 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 93.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 95.1% YoY -- genuine top-line momentum — Growth
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 37.2 is moderate-to-rich — Value
- Price-to-book of 66.6x prices in significant intangible value — Value
- Debt-to-equity of 3.42 adds balance-sheet risk to the value case — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
52/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 87%
of 192 Healthcare peers
Value Analyst
neutral
45
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 93.6% shows genuine earnings power backing the valuation
− P/E of 37.2 is moderate-to-rich
Growth Analyst
bullish
60
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 95.1% YoY -- genuine top-line momentum
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
49
/ 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement
− Price structure making lower highs and lower lows
Risk Analyst
bearish
32
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 3.42) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 51.8 to 52.2.
- Analyst(s) changed stance: News Analyst.
Analyst-level changes:
- News Analyst: stance neutral->bullish.
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
47.2
Neutral
MACD Histogram
-1.982
Bearish Momentum
Trend Direction
Downtrend
Weekly: Downtrend
Market Structure
Mixed
Support
$197.95
Resistance
$272.00
Bollinger %B
0.36
Inside Bands
Price vs Moving Averages
EMA 9
$231.13
Above
EMA 21
$237.32
Below
EMA 50
$245.64
Below
EMA 200
$292.63
Below
Fundamental Analysis
Valuation
36
Growth
62
Profitability
87
Financial Health
89
Cash Flow
70
Valuation
P/E Ratio
38.1×
P/B Ratio
22.90×
PEG Ratio
0.01
Dividend Yield
0.00%
52W High
$495.55
52W Low
$197.81
Quality & Growth
ROE
3975.6%
ROA
631.8%
Gross Margin
7971.9%
Operating Margin
2081.1%
Revenue Growth YoY
—
Debt / Equity
0.94
AI Fundamental Assessment
P/E ratio of 38.1 (rich relative to a 15-40x range); Price-to-book of 22.9x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 39.8%; Return on assets of 6.3%; Net margin of 16.8%; Gross margin of 79.7%; Current ratio of 3.05 (healthy short-term liquidity); Debt-to-equity of 0.94; Free cash flow per share is positive (4.07); Most recent quarter missed estimates by 23.7%; EPS growth decelerating (+84.1% -> -19.9% QoQ); Average YoY EPS growth of 337.2%; Analyst estimates rising over recent quarters
Get the Full ALNY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →